EUCTR2020-004902-67-ES进行中（未招募）1 期
A phase II single arm clinical trial assessing the efficacy and safety of BIntrafusp alfa (M7824) in previously treated advanced malignant pleural MESothelioma (BIMES). - BIMES
Fundación GECP0 个研究点目标入组 47 人开始时间: 2021年8月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged = 18 years and capable of giving signed informed consent or requirement per local legislation.
- •2. ECOG performance status of 0-2.
- •3. Histologically confirmed malignant pleural mesothelioma (all histological subtypes are eligible), unresectable advanced or metastatic.
- •4. Patients that progressed or be intolerant to = 2 regimens of chemotherapy, including platinum-based chemotherapy with pemetrexed. Prior bevacizumab treatment given during chemotherapy are allowed.
- •5. Evaluable disease or measurable disease as assessed according to the modified RECIST v1.1 criteria.
- •6. Availability of tumor tissue for translational research (at least 10 slides); Archival tumor tissue at diagnosis can be sent if it was obtained less than 18 months ago.
- •7. Life expectancy of at least 3 months.
- •8. Adequate hematologic and organ function defined by the following laboratory results obtained within 14 days prior to enrollment.
- •Hematologic: Absolute neutrophil count (ANC) = 1.5 × 109/L, platelet count = 100 × 109/L, and hemoglobin = 9 g/dL
- •Hepatic: Total bilirubin level = the upper limit of normal (UNL) range, AST and ALT levels = 1.5 x ULN and ALP = 2.5 x ULN. For participants with liver involvement in their tumor, AST =5 x ULN, ALT = 5 x ULN, and bilirubin = 3.0 x ULN.
- •Renal: Creatinine level =1.5 x ULN or estimated creatinine clearance = 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method) (may be modified to a higher creatinine clearance threshold, e.g. = 50 ml/min or = 60 ml/min as appropriate based on the target population or other drugs used in a combination regimen). For participants with Creatinine > 1.5 x ULN, glomerular filtration rate (GFR) can also be used.
- •Coagulation: normal international normalized ratio (INR), PT = 1.5 x ULN and activated partial thromboplastin time (aPTT) = 1.5 x ULN.
- •9. Stable HIV infection on ART for at least 4 weeks, no documented evidence of multi-drug resistance, viral load of < 400 copies/ml and CD4+ T-cells = 350 cells/µL.
- •10. Controlled HBV/HCV infection on a stable dose of antiviral therapy, HBV viral load below the limit of quantification. HCV viral load below the limit of quantification.
- •11. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.
- •12. For female patients of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception that results in a low failure rate (< 1% per year) when used consistently and correctly throughout the study and for at least 2 months after last bintrafusp alfa treatment administration .
- •13. For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception that results in a low failure rate [< 1% per year] when used consistently and correctly.
- •14. Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drugs. The same rules are valid for male patients involved in this clinical study if they have a partner of childbirth potential. Male patients must always use a condom. For male patients the duration of contraception after the last dose of bintrafusp alfa is 4 months.
- •15. Women who are not postmenopausal (= 12 month
排除标准
- •1. Prior immune checkpoint therapy with an anti-PD-1, anti-PD-L1, anti-CD137, or anti-CTLA-4 antibody.
- •2. Known severe hypersensitivity [Grade = 3 NCI CTCAE 5.0]) to investigational product or any component in its formulations, any history of anaphylaxis, or recent, within 5 months, history of uncontrollable asthma.
- •3. Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years. Participants with a history of cervical carcinoma in situ, superficial or noninvasive bladder cancer, localized prostate cancer or basal cell or squamous cell carcinoma in situ previously treated with curative intent and endoscopically resected GI cancers limited to the mucosal layer without recurrence in > 1 year are NOT excluded.
- •4. Active central nervous system (CNS) metastases and/or carcinomatous meningitis that require therapeutic intervention or are causing clinical symptoms. Patients with previously treated brain metastases may participate provided they are stable and are not using steroids for at least 7 days prior to randomization.
- •5. Prior major surgery within 4 weeks prior to the first dose of study intervention.
- •6. Unstable or unresolved surgical or chemotherapy-related toxicity that would compromise the patient’s capacity to participate in the trial. Persisting Grade > 1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade = 2 is acceptable.
- •7. Prior organ transplantation including allogenic stem-cell transplantation, except transplants that do not require immunosuppression.
- •8. Live vaccines given 30 days prior to first dose of protocol treatment (M7824). Seasonal flu vaccines that do not contain a live virus are permitted. Also, COVID-19 vaccines approved by the authorities that do not contain live virus are permitted.
- •9. Drug-induced interstitial lung disease (ILD) or participant has had a history of drug-induced pneumonitis that has required oral or IV steroids, and/or other diseases, which in the opinion of the Investigator might impair the participant’s tolerance for the study or ability to consistently participate in study procedures.
- •10. Active and serious autoimmune disease that might deteriorate upon treatment with immunotherapy. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) or topical therapy (e.g., steroids) for psoriasis or eczema is not considered a form of systemic treatment.
- •11. Ongoing clinically serious infections requiring systemic antibiotic or antiviral, antimicrobial, or antifungal therapy.
- •12. Known history of active tuberculosis or any active infection requiring systemic therapy.
- •13. Patients with diagnosed immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •14. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrol
研究者
相似试验
招募中
1 期
Clinical study to evaluate BO-112 plus pembrolizumab in patients with advanced melanomaAdvanced melanoma after progression to immunotherapyMedDRA version: 20.0Level: LLTClassification code 10027155Term: Melanoma skinSystem Organ Class: 100000004864EUCTR2020-003921-51-FRHighlight Therapeutics40
招募中
2 期
A clinical trial to evaluate the feasibility and efficacy of using Anastrozole before surgery for patients with hormone-related localized Breast Cancer with low proliferative capacityMalignant neoplasm of breastC04.557.470.200RBR-5pygzhjHospital de Câncer de Barretos
尚未招募
2 期
A research study to find The Effectiveness Of Varunmoola Kwatha Orally And Nirgundi Taila nasal drops In Kaphavrutta Vata disease With Special Reference To HypothyroidismCTRI/2020/03/024377DR Ashish Dattatray Kamble
进行中（未招募）
1 期
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer - OCTAVIAEpithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaMedDRA version: 9.1 Level: LLT Classification code 10033128 Term: Ovarian cancerMedDRA version: 9.1 Level: LLT Classification code 10016180 Term: Fallopian tube cancerMedDRA version: 9.1 Level: LLT Classification code 10061344 Term: Peritoneal neoplasmEUCTR2008-008336-85-GBF. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR189
进行中（未招募）
不适用
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer. - OCTAVIAEUCTR2008-008336-85-SEF. Hoffmann-La Roche Ltd.,Pharmaceuticals Division, PDR180